206 related articles for article (PubMed ID: 10980120)
21. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
22. Inactivation of p53 and Pten promotes invasive bladder cancer.
Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C
Genes Dev; 2009 Mar; 23(6):675-80. PubMed ID: 19261747
[TBL] [Abstract][Full Text] [Related]
23. Transitional cell carcinoma in fishing cats (Prionailurus viverrinus): pathology and expression of cyclooxygenase-1, -2, and p53.
Landolfi JA; Terio KA
Vet Pathol; 2006 Sep; 43(5):674-81. PubMed ID: 16966444
[TBL] [Abstract][Full Text] [Related]
24. Oncoprotein changes in the flat lesions with atypia and invasive neoplasms of the urinary bladder.
Kee KH; Lee MJ; Ro JY
Oncol Rep; 2001; 8(3):579-83. PubMed ID: 11295084
[TBL] [Abstract][Full Text] [Related]
25. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
26. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
27. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis.
He F; Mo L; Zheng XY; Hu C; Lepor H; Lee EY; Sun TT; Wu XR
Cancer Res; 2009 Dec; 69(24):9413-21. PubMed ID: 19951992
[TBL] [Abstract][Full Text] [Related]
28. Genetic and molecular markers of urothelial premalignancy and malignancy.
Cordon-Cardo C; Cote RJ; Sauter G
Scand J Urol Nephrol Suppl; 2000; (205):82-93. PubMed ID: 11144907
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
[TBL] [Abstract][Full Text] [Related]
30. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
31. Spindle cell carcinoma progressed from transitional cell carcinoma of the urinary bladder.
Terada T
Int J Clin Exp Pathol; 2012; 5(1):83-8. PubMed ID: 22295151
[TBL] [Abstract][Full Text] [Related]
32. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
33. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
34. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.
Dyrskjøt L; Kruhøffer M; Thykjaer T; Marcussen N; Jensen JL; Møller K; Ørntoft TF
Cancer Res; 2004 Jun; 64(11):4040-8. PubMed ID: 15173019
[TBL] [Abstract][Full Text] [Related]
35. Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer.
Ow K; Delprado W; Fisher R; Barrett J; Yu Y; Jackson P; Russell PJ
J Pathol; 2000 May; 191(1):39-47. PubMed ID: 10767717
[TBL] [Abstract][Full Text] [Related]
36. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index.
Wright C; Thomas D; Mellon K; Neal DE; Horne CH
Br J Urol; 1995 Feb; 75(2):173-9. PubMed ID: 7850321
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
38. Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma.
Ewald JA; Downs TM; Cetnar JP; Ricke WA
PLoS One; 2013; 8(2):e55414. PubMed ID: 23383328
[TBL] [Abstract][Full Text] [Related]
39. p53 mutations in bladder carcinoma cell lines.
Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
[TBL] [Abstract][Full Text] [Related]
40. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]